E3040 sulphate, a novel thromboxane synthase inhibitor, blocks the Cl− secretion induced by platelet-activating factor in isolated rat colon

British Journal of Pharmacology

Volumn 136, Issue 3, 2002, Pages 383-390

  Sakai, Hideki ^a   Suzuki, Tomoyuki ^a   Murota, Miki ^a   Oketani, Kiyoshi ^a,b   Uchiumi, Takaoki ^a   Murakami, Manabu ^b   Takeguchi, Noriaki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

Chloride secretion; Colon; E3040; E3040 sulphate; Inflammatory bowel disease; Organic anion transporter; Platelet activating factor; Thromboxane synthase

Indexed keywords

6 HYDROXY 5,7 DIMETHYL 2 METHYLAMINO 4 (3 PYRIDYLMETHYL)BENZOTHIAZOLE; ARACHIDONATE 5 LIPOXYGENASE; BENZOTHIAZOLE DERIVATIVE; CHLORIDE; ENZYME INHIBITOR; ORGANIC ANION TRANSPORTER; PROSTAGLANDIN SYNTHASE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2; THROMBOXANE SYNTHASE; 3 [4 (3 PYRIDYLMETHYL)PHENYL]METHACRYLIC ACID; 4 AMINOHIPPURIC ACID; 6 HYDROXY 5,7 DIMETHYL 2 METHYLAMINO 4 (3 PYRIDYLMETHYL)BENZOTHIAZOLE SULFATE; BROMSULFOPHTHALEIN; CHLORIDE ION; E 3040 SULFATE; INDOMETACIN; LEUKOTRIENE D4; PROBENECID; PROSTAGLANDIN E2; THROMBOXANE A2; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLOOD; COLON; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; IN VITRO STUDY; INTESTINE MUCOSA; METABOLISM; RAT; SECRETION; WISTAR RAT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; CHEMICAL STRUCTURE; CHLORIDE CURRENT; CHLORIDE TRANSPORT; COLON DISEASE; COLON MUCOSA; CONTROLLED STUDY; DRUG STRUCTURE; ENTERITIS; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BENZOTHIAZOLES; CHLORIDES; COLON; ENZYME INHIBITORS; FEMALE; INTESTINAL MUCOSA; ORGANIC ANION TRANSPORTERS; PLATELET ACTIVATING FACTOR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; RATS; RATS, WISTAR; THIAZOLES; THROMBOXANE B2; THROMBOXANE-A SYNTHASE; ANIMAL; IN VITRO; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; SUPPORT, NON-U.S. GOV'T;

EID: 0036016108     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704723     Document Type: Article

References (37)

1. Investigation of the effects of platelet-activating factor (PAF) on ion transport and prostaglandin synthesis in human colonic mucosa in vitro
2. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis
3. Patterns of prostaglandin synthesis and degradation in isolated superficial and proliferative colonic epithelial cells compared to residual colon
4. PAF-acether and acetylhydrolase in stool of patients with Crohn's disease
5. Neuronally mediated and direct effects of prostaglandins on ion transport in rat colon descendens
6. Role of platelet-activating factor in ulcerative colitis
7. OKY-1581, a potential selective thromboxane synthetase inhibitor
8. 2 and E-series prostaglandins
9. 2 synthetase: Synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives
10. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)
11. − secretion in rat distal colon in vitro
12. 2+ pathway in rat colonic crypt cells
13. +-independent organic anion transporter
14. Novel aspect of Crohn's disease: Increased content of platelet-activating factor in ileal and colonic mucosa
15. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes
16. Functional characterization of the basolateral rat liver organic anion transporting polypeptide
17. Evidence for a colonic PAF receptor
18. Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis
19. Role of cytokines and platelet-activating factor in inflammatory bowel disease: Implications for therapy
20. Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide
21. 2 synthetase, on eicosanoid production
22. Thromboxanes in inflammatory bowel disease - Pathogenic and therapeutic implications
23. − secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon
24. − secretion in isolated rat colon
25. Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients
26. Characterization of the efflux transport of 17β-estradiol-D-17β-glucuronide from the brain across the blood-brain barrier
27. − secretion by anti-diarrhea drug loperamide in isolated rat colon
28. − secretion induced by platelet-activating factor in isolated rat colon
29. Different biliary excretion systems for glucuronide and sulphate of a model compound; study using Eisai hyperbilirubinemic rats
30. Carrier-mediated active transport of the glucuronide and sulphate of 6-hydroxy-5, 7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole (E3040) into rat liver; quantitative comparison of permeability in isolated hepatocytes, perfused liver and liver in vivo
31. 2 receptor antagonist in an animal model of inflammatory bowel disease
32. Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: Therapeutic effects against 2, 4, 6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats
33. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis
34. Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis
35. Assessment of the role of platelet-activating factor in an animal model of inflammatory bowel disease
36. Platelet activating factor: Release from colonic mucosa in patients with ulcerative colitis and its effect on colonic secretion
37. Effect of anti-inflammatory bowel disease drug, E3040, on urate transport in rat renal brush border membrane vesicles